ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
ENTEROME ENTEROME
  • COMPANY
    • FOCUS
    • COLLABORATIONS
    • LEADERSHIP
  • TECHNOLOGY
    • PROGRAMS & PRODUCTS
  • PIPELINE
  • INVESTORS
  • NEWSROOM
    • PRESS RELEASES
    • CONFERENCES & EVENTS
  • CAREERS
  • CONTACT
Jan 05 2017

Enterome starts Phase I clinical trial with its lead candidate EB8018 to treat Crohn’s disease

EB8018 is a first-in-class oral small molecule targeting the host-microbiome interaction by blocking FimH

Paris, France and Cambridge, MA, USA – January 5, 2017

Enterome SA a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce the launch of a Phase 1 clinical study with its lead small molecule drug candidate EB8018, a small molecule designed to block FimH, as a potential new treatment for Crohn’s disease.

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract. Emerging evidence suggests that the microbiome plays an important role in triggering an abnormal mucosal immune response in patients with Crohn’s disease.

Enterome has identified the FimH adhesin from overabundant E. coli species as a potential novel target to block inflammation in Crohn’s disease through application of its metagenomics platform to the microbiomes of patients suffering from Crohn’s disease. Independent studies have also demonstrated an imbalance of the microbiomes of such patients with a significant increase of E. coli with invasive properties, termed adherent-invasive E. coli (AIEC). These AIEC bacteria attach to the gut wall of susceptible patients via the fimbrial adhesion protein FimH, and subsequently trigger inflammation by inducing local production of cytokines and invasion of the gut wall through activation of TLR4 and CEACAM6 receptors which are strongly upregulated in the ileum of Crohn’s disease patients.

EB8018 is an oral and non-systemic small molecule drug that is designed to block FimH thereby preventing local cytokine production and the entry of AIEC into the gut wall by selectively disarming the virulent bacteria without disrupting the gut microbiome. It represents a novel, non-biologic, non-steroidal, non-antibiotic, non-immunomodulatory and local approach for the treatment of Crohn’s disease. Enterome in-licensed EB8018 from Vertex Pharmaceuticals Inc.

The phase 1 clinical study is designed to determine the safety and tolerability profile of single and multiple doses of EB8018 in healthy subjects. The study will also assess the pharmacokinetic profile of single and multiple doses of EB8018 and the effects of EB8018 on the healthy gut microbiome. In parallel with the phase 1 study, Enterome is developing a non-invasive microbiome biomarker to identify patients that may benefit from treatment with EB8018.

Pierre Belichard, CEO of Enterome, said: “We are delighted to have started the clinical development of our lead drug candidate EB8018. This represents an important milestone for Enterome and validation of our capability to identify novel targets derived from the microbiome that we can use to develop small molecule drug candidates originating either from our internal resources or via in-licensing, as is the case with EB8018. We look forward to reporting the results from the phase 1 study later in 2017.”

 

> Press Release (english version)

> Press Release (french version)

Comments are closed.

Categories

  • PRESS RELEASES
  • PRESS RELEASES 2020
  • PRESS RELEASES 2019
  • PRESS RELEASES 2018
  • PRESS RELEASES 2017
  • PRESS RELEASES 2016
  • PRESS RELEASES 2015
  • PRESS RELEASES 2014
  • CAREERS
  • PRESS
ETEROME-Bioscience

ENTEROME

94/96 avenue Ledru-Rollin
75011 PARIS, FRANCE
Tel : +33 (0)1 75 77 27 85
Email : info@enterome.com

INFORMATIONS

RCS Paris N° 508 580 289
Siret : 50858028900025
NAF : 7211Z
N° TVA : FR40 508 580 289

Legal notice • Privacy Policy • Cookie Policy
2021 ENTEROME — All rights reserved.
Lors de votre navigation sur notre site internet, nous sommes susceptibles de déposer des cookies sur votre appareil à des fins d’analyses et de performances. Vous avez la possibilité d’accepter, de refuser ou de paramétrer le dépôt de cookies.

When you navigate on our website, we may deposit cookies on your device for analysis and performance purposes. You are able to accept, refuse or configure the cookies' deposit. [ Read More ]

Cookie settings Reject Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Read more about our Privacy Policy.
Necessary
Always Enabled

The cookies defines under this category are absolutely essential for the website to function. Hence they are loaded by default irrespective if user consent.

CookieDescription
cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-non-necessaryThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Non Necessary".
PHPSESSIDThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytics

Analytics cookies help us understand how our visitors interact with the website. It helps us understand the number of visitors, where the visitors are coming from, and the pages they navigate. The cookies collect this data and are reported anonymously.

CookieDescription
_gaThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gidThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Performance

These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is aggregated and therefore anonymous. It is only used to improve how a website works.

CookieDescription
_gatThis cookies is installed by Google Universal Analytics to throttle the request rate to limit the colllection of data on high traffic sites.